Targeted therapy in the management of non–small-cell lung cancer is discussed.
Real-World Impact of Prophylactic Pegfilgrastim in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With or Without Rituximab Chemotherapy in Korea
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL.
Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented.
The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed.
Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)
Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results.
Results 1 - 5 of 5